Fundraising FoxCordio
Israel corporation · 5 known investors
Find your way into Cordio
Sign up to find every way you can get introduced to Cordio
- Your email: who you already know at Cordio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cordio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Cordio Medical develops medical-grade digital health solutions that use speech signal processing algorithms to help patients monitor and manage their health, with a focus on cardiovascular and heart failure care. Its products are used by healthcare professionals and patients.
Founders & leadership
CL
Chaim LotanNamed on SEC filing
RH
Ronit HavivNamed on SEC filing
DL
David LifschitzNamed on SEC filing
IS
Ilan ShalomNamed on SEC filing
LE
Leon EtingNamed on SEC filing
IK
Itai KatsirNamed on SEC filing
Board
EL
LS
Lior ShahoriBoard director
TT
Investors · 5
Peregrine Ventures✓ confirmed by CordioOr Yehuda · $500K – $3M
How we know: Peregrine Ventures's portfolio page · the company's own site · funding news · prnewswire.com · Not right? Tell us
Incentive, Peregrine Ventures Incubatorlisted by Incentive, Peregrine Ventures IncubatorOr Yehuda
How we know: Incentive, Peregrine Ventures Incubator's portfolio page · Not right? Tell us
Pix Vine Capitallisted by Pix Vine CapitalSingapore · $250K – $500Kvia Patrick De Silva · inferred
How we know: Pix Vine Capital's portfolio page · Not right? Tell us
PeregrinereportedSan Francisco
How we know: press coverage · Not right? Tell us
Also in the syndicate · 1
CEROS
Reported raises · per SEC filings
Form D private placements$13.6M disclosed across 1 of 2 rounds · 2021–2022
▶$13.6MraisedJan 2022 · 10 investors · Other Health CareRule 506(b)
▶$13.6MraisedJan 2022 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Chaim LotanExecutive Officer, Director
- Ronit HavivExecutive Officer
- David LifschitzDirector
- Eyal LifschitzExecutive Officer, Director
- Lior ShahoriDirector
- Tamir TalExecutive Officer
- Ilan ShalomExecutive Officer
- Leon EtingExecutive Officer
- Itai KatsirExecutive Officer
- Offering amount
- $16M
- Amount sold
- $13.6M
- Minimum investment
- $50K
- Sales commissions
- $1.2M
- Placement agents
- Aegis Capital Corp.
- First sale
- Sep 2021
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
ProlaioProlaio develops continuous, predictive heart data monitoring using high-density data capture and advanced analytics to support cardiovascular therapy development and patient care. It serves patients and drug developers in cardiology, aiming to replace episodic monitoring with real-world data and AI-based tools.
AliveCorAliveCor develops digital health solutions focused on cardiovascular care, serving employers and healthcare payers seeking enterprise heart health platforms.
CardiosenseCardiosense develops wearable sensing hardware and deep-learning algorithms that convert physiological signals into clinical insights for cardiovascular disease detection and management. Its FDA De Novo-cleared platform supports pressure-guided heart failure management for clinicians across hospital and home care settings.
Aviary HealthAviary Health provides virtual and hybrid clinical programs — including cardiac rehabilitation, pulmonary rehabilitation, and chronic care management — combining AI-powered workflows with clinical teams. It serves hospitals and health systems, delivering end-to-end support for complex service lines.
Icardio.AIiCardio.ai develops artificial intelligence software to automate the interpretation and analysis of echocardiogram ultrasound imaging for cardiologists. The company partners with ultrasound equipment manufacturers to deliver automated diagnostic and measurement tools to clinicians globally.
Creative Destruction LabCreative Destruction Lab (CDL) is a global startup program for seed-stage, science-based companies that pairs founders with experienced entrepreneurs, angel investors, economists, and scientists through an objectives-based mentoring process. Affiliated with the University of Toronto's Rotman School of Management, it operates across multiple university sites worldwide with streams in areas such as AI, quantum, climate, and fintech.
HeartFlowHeartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD). Its platform, Heartflow One, is used by cardiologists and clinicians to guide diagnosis and treatment decisions for patients.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Cordio.
In the news
Frequently asked questions
- What does Cordio do?
- Cordio Medical develops medical-grade digital health solutions that use speech signal processing algorithms to help patients monitor and manage their health, with a focus on cardiovascular and heart failure care. Its products are used by healthcare professionals and patients.
- Who are Cordio's investors?
- Cordio's investors include Peregrine Ventures, Incentive, Peregrine Ventures Incubator, Pix Vine Capital, Peregrine.
- How much funding has Cordio raised?
- Cordio has disclosed $13.6M raised across 1 of its 2 known rounds.